In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- November 1, 2007 MicroRNAs put their signatures on the heart Physiological Genomics
- September 4, 2007 MicroRNAs: Powerful new regulators of heart disease and proactive therapeutic targets The Journal of Clinical Investigation
- April 27, 2007 Control of stress-dependent cardiac growth and gene expression by a microRNA Science
- October 4, 2006 A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure Proceedings of the National Academy of Sciences